Clinical trial · Observational
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Dysregulation of Hematopoiesis in Fanconi Anemia
NCT00900055CI-TRIAL-00059480completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Analyzing tissue and blood samples from healthy volunteers or patients with Fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory may help doctors learn more about the causes of blood cancers. PURPOSE: The purpose of this study is to analyze in the laboratory blood and bone marrow cells from healthy volunteers or patients with Fanconi anemia, myeloproliferative disorders, or myeloma.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloproliferative Disorders | Myeloproliferative Neoplasm | ALIAS | 0.90 |
| Fanconi Anemia | — | UNRESOLVED | — |
| Multiple Myeloma and Plasma Cell Neoplasm | — | UNRESOLVED | — |
| Myelodysplastic/Myeloproliferative Neoplasms | Myelodysplastic/Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (9)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chromatography | Other | — | UNRESOLVED |
| high performance liquid chromatography | Other | — | UNRESOLVED |
| immunoenzyme technique | Other | — | UNRESOLVED |
| microarray analysis | Genetic | — | UNRESOLVED |
| polyacrylamide gel electrophoresis | Genetic | — | UNRESOLVED |
| polymerase chain reaction | Genetic | — | UNRESOLVED |
| protein expression analysis | Genetic | — | UNRESOLVED |
| reverse transcriptase-polymerase chain reaction | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (7)
- measure
- Loss of function analyses
- timeFrame
- Duration of the study
- measure
- Proteins binding to Fanconi anemia, complementation group C (FACC) gene-product by affinity chromatography of nuclear and whole cell lysates of normal cells
- timeFrame
- Duration of the study
- measure
- Screening of proteins binding to FACC gene-product using monoclonal antibodies specific to signal transduction and cell cycle proteins
- timeFrame
- Duration of the study
- measure
- Microsequencing of unique proteins
- timeFrame
- Duration of the study
- measure
- Location of specific downstream block point imposed by antisense molecules using antibodies specific to signal transduction, cell cycle, or repair proteins for the FACC protein
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 55 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Meets 1 of the following criteria:
* Diagnosis of one of the following:
* Fanconi's anemia requiring bone marrow biopsy as part of standard care (adults and children)
* Myeloproliferative disorder or myeloma (adults)
* Healthy volunteer, meeting 1 of the following criteria:
* Over 18 years of age
* Bone marrow transplant donor (children)
PATIENT CHARACTERISTICS:
* Hemoglobin \> 13 g/dL
* White blood cells (WBC) \> 4,000/mm³
* Platelet count \> 150,000/mm³
* No clinical signs or symptoms of acute or subacute infections (viral, bacterial, or fungal)
* No known blood abnormality (healthy volunteers)
* No allergies to lidocaine or xylocaine
PRIOR CONCURRENT THERAPY:
* Not specifiedReferences
Publications (0)
Data not yet available
No reference posted for this study.